ERBB2 and gastric cancer: A recent study21 demonstrated that dysregulation of the CCND1–CDK4/6‐Rb axis contributes to pyrotinib resistance, and that CDK4/6 inhibitor (SHR6390) sensitizes pyrotinib in a HER2‐positive advanced gastric cancer mouse model.